ArkeaBio raises $26.5M for methane reducing vaccine

U.S. based start-up ArkeaBio™ has raised $26.5 million to reduce greenhouse gas emissions with its methane vaccine. Series A investment will advance methane reducing vaccine R&D, providing farmers cost-effective and executable climate solutions, while also ensuring companies can address their GHG reduction commitments.

ArkeaBio raises $26.5M for methane reducing vaccineArkeaBio™, an ag-biotech start-up developing a vaccine to reduce livestock methane emissions, has announced the close of a $26.5 million Series A financing round. The raise was led by current investor Breakthrough Energy Ventures (BEV), and attracted additional investors, including The Grantham Foundation for the Protection of the Environment, AgriZeroNZ, Rabo Ventures, Overview Capital, and The51 Food & AgTech Fund.

ArkeaBio expects the vaccine to provide an innovative, cost-effective, and scalable solution to reduce the world’s livestock methane emissions, which currently generate the equivalent of 3 billion tonnes of CO2 annually and represent 6% of annual greenhouse gas emissions. “Reducing methane emissions from the agricultural sector is one of the most pressing challenges in today’s fight against climate change,” said Chris Rivest, Chairman of the Board at ArkeaBio and partner at Breakthrough Energy Ventures. “ArkeaBio’s approach using innovative vaccine technologies will create effective and massively scalable solutions to reduce on-farm methane emissions, leaving them well-positioned to redefine the agricultural landscape in the years to come.”

ArkeaBio unveiled that its research and development results have garnered substantial attention from investors for the advancement of the inaugural methane-reducing vaccine, designed for safe and rapid implementation within existing on-farm practices. The company expects the funds raised in this Series A financing to play a pivotal role in expanding the research, development and deployment of the vaccine, including large-scale field trials and engagement along the supply chain.

“We are thankful for the financial support, confidence, and trust of our investors. This funding will accelerate the development of our vaccine-based solution to meet a pressing global problem,” said Colin South, ArkeaBio CEO. “To echo the sentiments of The Grantham Foundation: ‘climate change is the greatest challenge humanity has ever faced. It is the race of our lives.’ This capital raise allows us to continue to create the tools necessary for farmers to achieve globally relevant reductions in livestock methane emissions.”

ArkeaBio emphasized its dedication to collaborative efforts with industry partners, regulatory authorities, and environmental organizations to bring this transformative solution to market.